A Study to Learn How the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
37actual
Sites
1
Country
Belgium
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Study was terminated early . This decision was not due to any safety concerns associated with PF-07899895 but rather due to a business decision.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-17 | actual | When the study began enrolling |
| Primary completion | 2025-10-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-24 | actual | The whole study's end, after follow-up |
| First posted | 2023-11-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Interventions
- Drug: PF-07899895
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFAE observed after single or multiple doses
measured Day 1 up to Day 28 (Part A)/Day 1 up to Day 38 (Part B)
Laboratory abnormalities following single or multiple ascending doses
measured Day 1 up to Day 28 (Part A)/Day 1 up to Day 38 (Part B)
Vital sign changes following single or multiple ascending doses
measured Day 1 up to Day 28 (Part A)/Day 1 up to Day 38 (Part B)
ECG changes following single or multiple ascending doses
measured Day 1 up to Day 28 (Part A)/Day 1 up to Day 38 (Part B)
Changes in physical examination after single or multiple ascending doses
measured Day 1 up to Day 28 (Part A)/Day 1 up to Day 38 (Part B)
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed